Jennison Associates LLC bought a new stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 78,650 shares of the company's stock, valued at approximately $3,300,000. Jennison Associates LLC owned 0.61% of Neurogene as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Quest Partners LLC acquired a new position in Neurogene during the second quarter worth $55,000. SG Americas Securities LLC acquired a new position in Neurogene during the first quarter worth $120,000. Rhumbline Advisers acquired a new position in Neurogene during the second quarter worth $491,000. Avoro Capital Advisors LLC acquired a new position in Neurogene during the second quarter worth $802,000. Finally, Bank of New York Mellon Corp acquired a new position in Neurogene during the second quarter worth $1,107,000. Institutional investors and hedge funds own 52.37% of the company's stock.
Neurogene Price Performance
NGNE traded up $4.71 during trading on Friday, hitting $20.30. 1,062,923 shares of the company traded hands, compared to its average volume of 551,448. The stock's fifty day moving average is $44.97 and its 200 day moving average is $39.57. Neurogene Inc. has a one year low of $12.49 and a one year high of $74.49.
Wall Street Analyst Weigh In
Several research analysts have weighed in on NGNE shares. BMO Capital Markets lowered their price objective on shares of Neurogene from $60.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday. Leerink Partners upped their target price on shares of Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 12th. William Blair reiterated an "outperform" rating on shares of Neurogene in a research note on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of Neurogene in a research note on Tuesday. Finally, Stifel Nicolaus increased their price target on shares of Neurogene from $44.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Neurogene currently has an average rating of "Buy" and an average price target of $60.83.
Check Out Our Latest Stock Report on Neurogene
About Neurogene
(
Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Further Reading
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
